Yuhei YAMAGUCHI· @yymgcmd · X·· 2 天前评分45
正文 · 原文
In countries where both abemaciclib and ribociclib are available, choosing between them is challenging.
In Japan, the recent expansion of adjuvant abemaciclib to monarchE cohort 2 has somewhat narrowed the gap in eligible populations.
#ESMO26
129 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgAssociation of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE
https://esmocongress.esmo.orgMaintained iDFS benefit (Δ 5.3%) and favorable OS (Δ 2.1%) with adjuvant ribociclib after 6 years of follow up (all patients off ribo). Efficacy comparable to abema (monarchE), with different toxicity profile and wider population (N+ and high-risk N0). #ESMO26 #ESMOAmbassadors在 X 查看被引用的帖子
来源：Yuhei YAMAGUCHI · x.com